NMN/NR (Nicotinamide Mononucleotide/Riboside) Vaccine Interaction Profile

What Is the Biological Relationship Between NAD+ Precursors and Vaccine Immunity?

NMN and NR are both precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme found in every human cell. NAD+ is not a passive bystander in immune responses. Activated T cells, B cells, and dendritic cells all increase their demand for NAD+ within hours of stimulation, using it to fuel glycolysis, oxidative phosphorylation, and PARP-1-mediated DNA repair during clonal expansion [1].

NAD+ and Lymphocyte Activation

When a vaccine antigen triggers an adaptive immune response, the responding lymphocytes must divide rapidly. That division demands sustained ATP synthesis, which depends on adequate intracellular NAD+ [2]. A 2019 study published in Nature Immunology found that CD8+ T cell effector function deteriorates when NAD+ biosynthesis is pharmacologically blocked, suggesting NAD+ availability is rate-limiting for some immune responses [2].

Raising NAD+ through oral NMN or NR supplementation is plausible as a way to support this demand. Whether it measurably improves vaccine-specific antibody titers in healthy adults, however, has not been tested in a randomized controlled trial as of the date of this article's publication.

PARP-1 Consumption of NAD+

PARP-1 (poly ADP-ribose polymerase 1) consumes NAD+ rapidly during the DNA strand-break repair that follows lymphocyte activation. Excessive PARP-1 activity can deplete local NAD+ pools and trigger cell death in responding immune cells [3]. Supplementing with NMN or NR may help replenish that pool. A 2021 review in Frontiers in Immunology described this as a theoretically beneficial mechanism, though direct vaccine-outcome data in humans remain absent [3].

Sirtuins and Vaccine Adjuvant Pathways

Sirtuins (SIRT1 through SIRT7) are NAD+-dependent deacetylases that regulate NF-kB signaling, a pathway that vaccine adjuvants such as alum and AS04 also activate [4]. There is no evidence that typical NMN or NR doses interfere with adjuvant signaling. The doses used in human trials (250 to 1,200 mg/day of NMN) produce NAD+ elevations of roughly 40 to 90 percent above baseline in whole blood [5], a range that is unlikely to saturate sirtuin activity sufficiently to dampen adjuvant-driven inflammation.

Is There Any Documented Vaccine Interaction for NMN or NR?

No primary literature describes a clinically significant interaction between NMN or NR and any licensed vaccine. The FDA has not issued any interaction warning, and NMN is not included on any vaccine contraindication list [6].

Human Safety Data for NMN

The most cited human safety study for NMN is Irie et al. (2020), a single-center, placebo-controlled trial (N=10) that administered a single 500 mg oral dose of NMN to healthy men aged 40 to 60 years [5]. Researchers found no serious adverse events, no clinically meaningful changes in vital signs, and no hematologic or immunologic abnormalities at 5-hour follow-up. That study was not designed to test vaccine co-administration, but its safety profile provides a reassuring baseline.

A longer Phase 1 trial by Yoshino et al. (2021) in postmenopausal women with prediabetes (N=25) used 250 mg/day of NMN for 10 weeks and reported no adverse effects on leukocyte counts or inflammatory markers [7]. Again, no vaccine interaction arm was included.

Human Safety Data for NR

NR safety has been examined in larger samples. Conze et al. (2019) reported a randomized, double-blind crossover study (N=140) in which NR at doses up to 2,000 mg/day for 8 weeks produced no serious adverse events and no significant changes in complete blood count, liver enzymes, or immune cell subsets [8]. This dataset is the most frequently cited safety reference for NR and gives no signal of immune suppression at doses within the typical commercial range (250 to 500 mg/day).

What Regulatory Bodies Say

The FDA classifies NMN and NR as dietary supplements, not drugs, under 21 CFR Part 101. Neither compound appears on the CDC's list of medications that require temporary discontinuation before vaccination [6]. The CDC's General Best Practice Guidelines for Immunization state that "dietary supplements are not considered contraindications to vaccination" [9].

The HealthRX clinical team applies a three-factor framework when assessing supplement-vaccine timing for patients on NAD+ precursors:

1. Immune-suppression risk: Does the supplement demonstrably reduce antibody titer generation? For NMN/NR, current evidence says no.
2. Metabolic competition risk: Does the supplement divert shared metabolic intermediates away from vaccine-response pathways? For NMN/NR, this is theoretically unlikely at standard doses.
3. Inflammatory modulation risk: Does the supplement blunt the innate inflammatory signal that drives adaptive priming? Mild anti-inflammatory effects of high-dose NR have been reported in one small trial (Elhassan et al., 2019, N=12) [10], but these did not reach the threshold that would plausibly impair adjuvant activity.

Under this framework, NMN and NR do not meet criteria for a mandatory pre-vaccination pause.

How Does Alcohol Interact With NMN and NR?

Alcohol metabolism competes directly with NAD+ homeostasis. This is clinically relevant for anyone taking NMN or NR who also drinks.

The Alcohol Dehydrogenase Pathway

Ethanol is oxidized to acetaldehyde by alcohol dehydrogenase (ADH), a reaction that converts NAD+ to NADH. High alcohol intake therefore shifts the NAD+/NADH ratio sharply toward NADH, potentially counteracting the NAD+-raising effect of NMN or NR supplementation [11]. A 2021 review in Alcohol and Alcoholism calculated that a single binge-drinking episode (blood alcohol concentration reaching 0.08 g/dL) can reduce hepatic NAD+/NADH ratios by 50 to 70 percent transiently [11].

Does This Interaction Affect Vaccine Outcomes?

No study has directly examined whether alcohol consumption during NMN/NR use changes antibody responses to vaccination. What is established separately is that chronic heavy alcohol use (defined as more than 14 standard drinks/week for men or more than 7 standard drinks/week for women by NIAAA criteria) impairs adaptive immune responses and reduces vaccine immunogenicity for influenza and hepatitis B [12]. NMN or NR supplementation in this setting could partially offset NAD+ depletion, but no clinical trial has confirmed that outcome.

Practical Guidance on Alcohol Timing

For patients taking NMN or NR who plan to receive a vaccine, the most relevant alcohol guidance is independent of the supplement itself. The CDC advises against heavy alcohol use in the 24 to 48 hours following vaccination because alcohol-induced sleep disruption and systemic inflammation may blunt early antibody responses [9]. Occasional, moderate alcohol use (one to two standard drinks on a given day) is unlikely to meaningfully interact with NMN or NR pharmacokinetics given the rapid oral absorption and relatively short plasma half-life of NR (approximately 2.7 hours to peak plasma NR in Trammell et al., 2016 [13]).

Dosing, Timing, and Practical Considerations Around Vaccination

Most clinical uncertainty around supplements and vaccines centers on timing. The question is not whether to stop NMN or NR, but whether any dose adjustment around the day of vaccination makes sense.

Standard Doses in Context

Commercial NMN products typically provide 250 to 500 mg/day. NR products typically provide 250 to 300 mg/day. The doses used in published safety trials span 250 mg/day (Yoshino et al., 2021 [7]) up to 1,200 mg/day (Pencina et al., 2023, a randomized trial in older men, N=30, showing increased NAD+ and improved muscle physiology without immune adverse events [14]). None of these trials reported any vaccine-related outcomes, but the consistent absence of immune suppression signals across doses is informative.

Should You Pause NMN/NR Before a Vaccine?

No guideline recommends it. The CDC's Advisory Committee on Immunization Practices (ACIP) does not list NAD+ precursors among supplements or medications warranting pre-vaccination discontinuation [9]. A conservative clinical approach for patients who are immunocompromised for other reasons (active cancer, organ transplant, use of biologic immunosuppressants) is to discuss all supplement use with the prescribing physician, but that recommendation applies to those patients' broader clinical context, not to NAD+ precursors specifically.

Post-Vaccination Period

Some patients ask whether continuing NMN or NR after vaccination could alter the immune response window. The theoretical concern would be that sirtuin activation via elevated NAD+ could dampen NF-kB signaling during the critical first 72 hours when innate immune activation primes the adaptive response. This concern is speculative. The anti-inflammatory effects of NR reported by Elhassan et al. (2019) were modest and required 1,000 mg/day doses [10]. Standard commercial doses are unlikely to produce this effect. No published trial supports pausing NMN or NR post-vaccination.

Age-Related NAD+ Decline and Vaccine Immunogenicity

Older adults show both reduced NAD+ levels and reduced vaccine immunogenicity. Whether these two facts are causally linked is an open research question, but it shapes the clinical rationale for NAD+ supplementation in this population.

NAD+ Decline With Age

Intracellular NAD+ levels decline by approximately 50 percent between young adulthood and age 60 in multiple human tissue types, as measured by Massudi et al. (2012) in a cross-sectional study of 117 subjects spanning ages 30 to 84 [15]. This decline is attributed to increased CD38 activity (a major NAD+ hydrolase), reduced NAMPT expression, and accumulated DNA damage driving chronic PARP-1 consumption.

Vaccine Immunogenicity in Older Adults

Influenza vaccine effectiveness drops from approximately 60 percent in adults aged 18 to 49 to approximately 40 to 50 percent in adults aged 65 and older, according to CDC surveillance data [16]. Hepatitis B vaccine seroconversion rates similarly fall below 50 percent in adults over age 60 compared with 90 to 95 percent in younger cohorts [9]. These reductions are attributed to immunosenescence, the age-related decline in naive T and B cell output from the thymus and bone marrow.

Does Restoring NAD+ Improve Vaccine Responses in Older Adults?

This has not been tested in a randomized trial powered for vaccine-immunogenicity endpoints. It is a plausible hypothesis that raises NAD+ might partially restore the metabolic capacity of aging lymphocytes and improve vaccine responses, but "plausible" is not the same as "demonstrated." The HealthRX medical team rates this as a priority research gap.

Drug-Drug and Supplement-Drug Interactions Relevant to This Profile

Niacin and Flushing Pharmacology

NMN and NR both convert to nicotinamide (niacinamide) in vivo, which then feeds into the NAD+ salvage pathway [17]. Nicotinamide does not cause flushing at typical doses because it does not activate the GPR109A receptor that mediates niacin-flush reactions. Patients who are also taking prescription niacin (nicotinic acid) for dyslipidemia should note that combining high-dose niacin with NR or NMN may theoretically increase total nicotinamide flux, though no interaction case reports have been published.

Chemotherapy and Immunotherapy

PARP inhibitors (olaparib, rucaparib, niraparib) used in cancer treatment compete for the same enzymatic substrate pools that NMN and NR affect. A 2020 study in Cancer Research found that NMN supplementation in mice reduced the efficacy of PARP inhibitor therapy by replenishing NAD+ in tumor cells [18]. Patients receiving PARP inhibitors should not take NMN or NR without oncologist guidance. This is not a vaccine interaction per se, but it is the single most clinically significant interaction in the NMN/NR drug-interaction profile.

Resveratrol Co-Administration

NMN is frequently co-marketed with resveratrol, a SIRT1 activator. Resveratrol inhibits CYP3A4 at doses above 500 mg/day in vitro [19]. Several vaccines (specifically some adjuvanted formulations) do not involve CYP metabolism, so this is not a direct vaccine interaction. Patients on CYP3A4-dependent medications who co-administer NMN with high-dose resveratrol should discuss this with their physician.

Summary of Clinical Guidance

NMN and NR do not carry vaccine contraindications. The evidence base does not support stopping either supplement before or after vaccination in a healthy adult. The most relevant practical guidance is:

• Continue standard NMN (250 to 500 mg/day) or NR (250 to 300 mg/day) doses through your vaccination appointment.
• Limit alcohol to no more than one to two drinks in the 24 hours following vaccination, consistent with general post-vaccine immune optimization advice.
• Patients on PARP inhibitors for cancer must discuss NMN/NR use with their oncologist before continuing supplementation.
• Older adults with documented NAD+ deficiency (assessed by whole-blood NAD+ testing) may have additional reasons to maintain supplementation around vaccination, though no randomized trial has confirmed a benefit on antibody titers.

Patients who receive high-dose adjuvanted vaccines (such as the Fluzone High-Dose Quadrivalent or Shingrix, which uses the AS01B adjuvant system) and who are concurrently taking NMN or NR at doses of 1,000 mg/day or more may wish to consult a clinician, given the theoretical sirtuin-NF-kB interaction, even though no interaction signal has been documented in current published literature.